Observational studyHuman vaccines & immunotherapeutics2025
Mpox vaccination hesitancy and its associated factors among the general population in China: A national observational study.
Observational study in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mpox, formerly known as monkeypox, has been spread to more than 100 countries until now. Vaccines are vital measures to protect against mpox infection. However, vaccine hesitancy remains a barrier to achieving widespread vaccination coverage. We aimed to investigate the prevalence of mpox vaccination hesitancy and its associated factors in China. We conducted a cross-sectional survey among 3669 participants aged 18 years and above in China from September 15 to October 9, 2024. The main outcomes measured were the hesitancy to get vaccinated against mpox for oneself and for one's children. Data were analyzed using chi-square tests and logistic regression model. The overall hesitancy rate for mpox vaccination was 28.4% for oneself and 24.5% for one's children. Higher hesitancy was observed among male individuals (30.8%), those aged >40 years (31.2%), married individuals (29.6%), and those with high mpox-related knowledge (30.9%). Multivariable logistic regression analysis showed that females had lower hesitancy (aOR = 0.84, 95% CI: 0.72-0.97), while individuals with high mpox-related knowledge had higher hesitancy (aOR = 1.23, 95% CI: 1.03-1.47). These findings provide valuable data for public health authorities to design effective strategies for mpox vaccination rollout in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.